Review summary
Teaching objective: Recognize multiple sclerosis in a professional musician of 28 whose numbness and clumsiness of the fingers and fatigue could be put down to overwork or stress, as hers were for years, and care for it on the AAN 1965 disease-modifying therapy guideline, the ECTRIMS/EAN 1965 guideline and NICE NG220: urgent MRI of the brain and spine with gadolinium; diagnosis by the 1964 McDonald criteria (and their 1971 revision), with cerebrospinal fluid oligoclonal bands and exclusion of mimics (vitamin B12, thyroid, aquaporin-4 antibody for a myelitis; MOG antibody only when the picture suggests it); high-dose corticosteroids for a disabling relapse; early high-efficacy disease-modifying therapy, choosing among ocrelizumab, ofatumumab and natalizumab with JCV antibody status, infusion logistics and pregnancy plans; hepatitis B screening, immunoglobulins and vaccinations before B-cell therapy; vitamin D; infection and pseudo-relapse; fatigue; hand function with occupational therapy; and a plan built around her playing and teaching, set against the four years it took to name her illness in the 1970s, when no disease-modifying treatment existed.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| 26 January 1945 | Born in Oxford, England. | CLM-0001 |
| March 1961 | Formal debut at Wigmore Hall, London, at 16, after the Suggia Award and the Queen's Prize. | CLM-0002 |
| 1965 | Records the Elgar Cello Concerto. | CLM-0003 |
| June 1967 | Converts to Judaism and marries. | CLM-0004 |
| 1971 | Loses sensitivity in her fingers; returns to England exhausted and takes a sabbatical; the numbness worsens on her return to the stage in 1972. | CLM-0005, CLM-0006 |
| February 1973 | Last public concerts, in London and New York. | CLM-0007 |
| October 1973 | Diagnosed with multiple sclerosis in London at 28; her performing career ends. | CLM-0008, CLM-0010 |
| 1976 | Appointed OBE; teaches and gives master classes, and raises funds for MS research. | CLM-0009, CLM-0011 |
| 19 October 1987 | Dies of multiple sclerosis in London at 42. | CLM-0012 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Jacqueline Mary du Pré was born in Oxford, England, on 26 January 1945. Her mother was a pianist who had studied at the Royal Academy of Music, and her father an accountant. | confirmed | Jacqueline du Pré supports Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports du Pré, Jacqueline (1945-1987) (Women in World History: A Biographical Encyclopedia) supports HISTMED Master Roster v3 context |
| D | She began the cello as a small child, studied with William Pleeth at the Guildhall School of Music from the mid-1950s, won the Guilhermina Suggia Award at 11 in 1956 and the Queen's Prize at 15, attended a Pablo Casals masterclass in Zermatt in 1960, and made her formal debut at Wigmore Hall in London in March 1961, at 16. Anchors the modern social history: a professional cellist since her teens. |
confirmed | Jacqueline du Pré supports du Pré, Jacqueline (1945-1987) (Women in World History: A Biographical Encyclopedia) supports Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports |
| D | In 1965, at 20, she recorded Elgar's Cello Concerto with the London Symphony Orchestra under Sir John Barbirolli; she played chiefly on the Davidov Stradivarius of 1712. Her documented career anchors the modern plan built around hand function and performance. |
confirmed | Jacqueline du Pré supports Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports |
| D | She converted to Judaism and married her husband, a pianist and conductor, in Jerusalem in June 1967. History only; her husband is not named and is given no role in the modern episode. |
confirmed | Jacqueline du Pré supports |
| D | In 1971 her playing declined as she began to lose sensitivity in her fingers and other parts of her body; she returned to England exhausted, took a sabbatical from 1971 to 1972 and performed only rarely. When she resumed in 1972 the numbness in her fingers worsened, with fatigue. The anchor for the modern presenting problem (numbness and clumsiness of the hands, fatigue). |
confirmed | Jacqueline du Pré supports Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports Dacy LC, Rodriguez M. The interrupted concerto: Jacqueline du Pré and MS (Hektoen International, Fall 2014) supports |
| R | Two physicians writing about her illness note episodes of blurred vision in her teens, which they read as possibly an early sign of multiple sclerosis. Retrospective interpretation; not used as part of the modern history. |
possible | Dacy LC, Rodriguez M. The interrupted concerto: Jacqueline du Pré and MS (Hektoen International, Fall 2014) supports |
| D | Her last public concerts were in February 1973, in London, where she played the Elgar Concerto, and in New York. Dates the end of her performing; the modern index visit follows it. |
confirmed | Jacqueline du Pré supports Dacy LC, Rodriguez M. The interrupted concerto: Jacqueline du Pré and MS (Hektoen International, Fall 2014) supports |
| D | She was diagnosed with multiple sclerosis in London in October 1973, at 28, about four years after her first symptoms; the diagnosis ended her career as a performer. The documented diagnosis to which the modern diagnosis is linked. |
confirmed | Jacqueline du Pré supports Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports |
| D | She went on teaching and giving master classes, singing or whistling the musical lines and explaining the fingering when she could no longer play, and remained a teacher and mentor until her death. She was appointed an Officer of the Order of the British Empire in the 1976 New Year Honours. Her documented teaching anchors the modern plan built around her music. |
confirmed | du Pré, Jacqueline (1945-1987) (Women in World History: A Biographical Encyclopedia) supports Jacqueline du Pré supports Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports |
| R | Corticosteroids were the treatment available to her; physicians writing later judge that her illness followed a relapsing-remitting course that became secondary progressive. Retrospective; the published reviews note that no medical records are public. |
probable | Dacy LC, Rodriguez M. The interrupted concerto: Jacqueline du Pré and MS (Hektoen International, Fall 2014) supports Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports |
| D | After her diagnosis and retirement she raised funds for multiple sclerosis research; fellowships in her name later funded travel grants for early-career MS researchers. History only. |
confirmed | Dacy LC, Rodriguez M. The interrupted concerto: Jacqueline du Pré and MS (Hektoen International, Fall 2014) supports |
| D | She died of multiple sclerosis in London on 19 October 1987, at 42, and was buried in Golders Green Jewish Cemetery. One reference work gives 20 October. The documented death from multiple sclerosis. History only, stated without detail. |
confirmed | Jacqueline du Pré supports Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports du Pré, Jacqueline (1945-1987) (Women in World History: A Biographical Encyclopedia) supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this week | resolved | confirmed | active | CLM-0005, CLM-0007 |
| S | Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 1964 McDonald criteria and the 1971 revision; synthetic modern detail linked to her documented diagnosis | active | confirmed | both_with_link | CLM-0008, CLM-0012, CLM-0010 |
| S | Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosis | active | confirmed | active | CLM-0008, CLM-0012 |
| S | Acute uncomplicated cystitis (Escherichia coli) seven weeks after the first ocrelizumab course, with a pseudo-relapse: two days of returning tingling in the fingers with a low fever and no new neurological deficit; resolved | resolved | confirmed | active | CLM-0008, CLM-0012 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 1973-03-09 | Hemoglobin [Mass/volume] in Blood | 13.4 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1973-03-09 | Leukocytes [#/volume] in Blood by Automated count | 6.4 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1973-03-09 | Lymphocytes [#/volume] in Blood by Automated count | 1.9 10*3/uL Reference 1-4.8 10*3/uL |
http://loinc.org · 731-0 |
| S | 1973-03-09 | Platelets [#/volume] in Blood by Automated count | 246 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1973-03-09 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1973-03-09 | Potassium [Moles/volume] in Serum or Plasma | 4.2 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1973-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.72 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1973-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1968)/1.73 sq M | 117 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1973-03-09 | Glucose [Mass/volume] in Serum or Plasma | 86 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1973-03-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 16 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1973-03-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1973-03-09 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 468 pg/mL Reference 232-1245 pg/mL |
http://loinc.org · 2132-9 |
| S | 1973-03-09 | Thyrotropin [Units/volume] in Serum or Plasma | 1.6 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 1973-03-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 1973-03-09 | 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] | 26 s | http://loinc.org · 83157-8 |
| S | 1973-03-09 | 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] | 33.5 s | http://loinc.org · 83156-0 |
| S | 1973-03-23 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 16 ng/mL (low) Reference Below 20 ng/mL deficient; 20 to 29 insufficient |
http://loinc.org · 62292-8 |
| S | 1973-03-23 | IgG [Mass/volume] in Serum or Plasma | 1080 mg/dL Reference 700-1600 mg/dL |
http://loinc.org · 2465-3 |
| S | 1973-03-23 | IgM [Mass/volume] in Serum or Plasma | 124 mg/dL Reference 40-230 mg/dL |
http://loinc.org · 2472-9 |
| S | 1973-03-23 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | http://loinc.org · 44261-6 |
| S | 1973-03-23 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | http://loinc.org · 70274-6 |
| S | 1973-03-23 | 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] | 24.5 s | http://loinc.org · 83157-8 |
| S | 1973-03-23 | 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] | 31 s | http://loinc.org · 83156-0 |
| S | 1973-04-27 | Hemoglobin [Mass/volume] in Blood | 13.6 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1973-04-27 | Leukocytes [#/volume] in Blood by Automated count | 7.9 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1973-04-27 | Lymphocytes [#/volume] in Blood by Automated count | 1.6 10*3/uL Reference 1-4.8 10*3/uL |
http://loinc.org · 731-0 |
| S | 1973-04-27 | Platelets [#/volume] in Blood by Automated count | 252 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1973-04-27 | Glucose [Mass/volume] in Serum or Plasma | 90 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1973-04-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1973-04-27 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1973-04-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | http://loinc.org · 44261-6 |
| S | 1973-04-27 | 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] | 20.5 s | http://loinc.org · 83157-8 |
| S | 1973-04-27 | 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] | 23 s | http://loinc.org · 83156-0 |
| S | 1973-06-15 | Leukocytes [#/volume] in Blood by Automated count | 10.2 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1973-06-15 | C reactive protein [Mass/volume] in Serum or Plasma | 14 mg/L (high) Reference <=5 mg/L |
http://loinc.org · 1988-5 |
| S | 1973-07-13 | Hemoglobin [Mass/volume] in Blood | 13.5 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1973-07-13 | Leukocytes [#/volume] in Blood by Automated count | 6.1 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1973-07-13 | Lymphocytes [#/volume] in Blood by Automated count | 1.5 10*3/uL Reference 1-4.8 10*3/uL |
http://loinc.org · 731-0 |
| S | 1973-07-13 | Platelets [#/volume] in Blood by Automated count | 240 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1973-07-13 | CD19 cells [#/volume] in Blood | 3 /uL (low) Reference 100-500 /uL |
http://loinc.org · 8116-6 |
| S | 1973-07-13 | IgG [Mass/volume] in Serum or Plasma | 990 mg/dL Reference 700-1600 mg/dL |
http://loinc.org · 2465-3 |
| S | 1973-07-13 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 ng/mL Reference Below 20 ng/mL deficient; 20 to 29 insufficient |
http://loinc.org · 62292-8 |
| S | 1973-07-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 1973-07-13 | 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] | 19 s | http://loinc.org · 83157-8 |
| S | 1973-07-13 | 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] | 20.5 s | http://loinc.org · 83156-0 |
| S | 1973-09-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
| S | 1973-10-12 | Hemoglobin [Mass/volume] in Blood | 13.7 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1973-10-12 | Leukocytes [#/volume] in Blood by Automated count | 6 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1973-10-12 | Lymphocytes [#/volume] in Blood by Automated count | 1.4 10*3/uL Reference 1-4.8 10*3/uL |
http://loinc.org · 731-0 |
| S | 1973-10-12 | Platelets [#/volume] in Blood by Automated count | 238 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1973-10-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1973-10-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1968)/1.73 sq M | 121 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1973-10-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1973-10-12 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1973-10-12 | IgG [Mass/volume] in Serum or Plasma | 930 mg/dL Reference 700-1600 mg/dL |
http://loinc.org · 2465-3 |
| S | 1973-10-12 | IgM [Mass/volume] in Serum or Plasma | 46 mg/dL Reference 40-230 mg/dL |
http://loinc.org · 2472-9 |
| S | 1973-10-12 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 38 ng/mL Reference Below 20 ng/mL deficient; 20 to 29 insufficient |
http://loinc.org · 62292-8 |
| S | 1973-10-12 | Hepatitis B virus surface Ab [Units/volume] in Serum | 6 m[IU]/mL (low) Reference 10 mIU/mL or more is protective |
http://loinc.org · 16935-9 |
| S | 1973-10-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
| S | 1973-10-12 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | http://loinc.org · 70274-6 |
| S | 1973-10-12 | 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] | 18.5 s | http://loinc.org · 83157-8 |
| S | 1973-10-12 | 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] | 19.5 s | http://loinc.org · 83156-0 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 1973-03-09 | Body height | 173 cm | 8302-2 | S |
| 1973-03-09 | Body weight | 63.5 kg | 29463-7 | S |
| 1973-03-09 | Body mass index (BMI) [Ratio] | 21.2 kg/m2 | 39156-5 | S |
| 1973-03-09 | Systolic blood pressure | 112 mm[Hg] | 8480-6 | S |
| 1973-03-09 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 1973-03-09 | Heart rate | 74 /min | 8867-4 | S |
| 1973-03-09 | Respiratory rate | 14 /min | 9279-1 | S |
| 1973-03-09 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1973-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1973-03-23 | Body height | 173 cm | 8302-2 | S |
| 1973-03-23 | Body weight | 63.4 kg | 29463-7 | S |
| 1973-03-23 | Body mass index (BMI) [Ratio] | 21.2 kg/m2 | 39156-5 | S |
| 1973-03-23 | Systolic blood pressure | 114 mm[Hg] | 8480-6 | S |
| 1973-03-23 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 1973-03-23 | Heart rate | 76 /min | 8867-4 | S |
| 1973-03-23 | Respiratory rate | 14 /min | 9279-1 | S |
| 1973-03-23 | Body temperature | 36.7 Cel | 8310-5 | S |
| 1973-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1973-04-27 | Body height | 173 cm | 8302-2 | S |
| 1973-04-27 | Body weight | 64.6 kg | 29463-7 | S |
| 1973-04-27 | Body mass index (BMI) [Ratio] | 21.6 kg/m2 | 39156-5 | S |
| 1973-04-27 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 1973-04-27 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 1973-04-27 | Heart rate | 72 /min | 8867-4 | S |
| 1973-04-27 | Respiratory rate | 14 /min | 9279-1 | S |
| 1973-04-27 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1973-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1973-07-13 | Body height | 173 cm | 8302-2 | S |
| 1973-07-13 | Body weight | 64 kg | 29463-7 | S |
| 1973-07-13 | Body mass index (BMI) [Ratio] | 21.4 kg/m2 | 39156-5 | S |
| 1973-07-13 | Systolic blood pressure | 110 mm[Hg] | 8480-6 | S |
| 1973-07-13 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 1973-07-13 | Heart rate | 70 /min | 8867-4 | S |
| 1973-07-13 | Respiratory rate | 14 /min | 9279-1 | S |
| 1973-07-13 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1973-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1973-10-12 | Body height | 173 cm | 8302-2 | S |
| 1973-10-12 | Body weight | 63.8 kg | 29463-7 | S |
| 1973-10-12 | Body mass index (BMI) [Ratio] | 21.3 kg/m2 | 39156-5 | S |
| 1973-10-12 | Systolic blood pressure | 112 mm[Hg] | 8480-6 | S |
| 1973-10-12 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 1973-10-12 | Heart rate | 68 /min | 8867-4 | S |
| 1973-10-12 | Respiratory rate | 14 /min | 9279-1 | S |
| 1973-10-12 | Body temperature | 36.5 Cel | 8310-5 | S |
| 1973-10-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1973-06-15 | Body height | 173 cm | 8302-2 | S |
| 1973-06-15 | Body weight | 63.6 kg | 29463-7 | S |
| 1973-06-15 | Body mass index (BMI) [Ratio] | 21.3 kg/m2 | 39156-5 | S |
| 1973-06-15 | Systolic blood pressure | 116 mm[Hg] | 8480-6 | S |
| 1973-06-15 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 1973-06-15 | Heart rate | 92 /min | 8867-4 | S |
| 1973-06-15 | Respiratory rate | 16 /min | 9279-1 | S |
| 1973-06-15 | Body temperature | 37.8 Cel | 8310-5 | S |
| 1973-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1973-09-14 | Body height | 173 cm | 8302-2 | S |
| 1973-09-14 | Body weight | 63.9 kg | 29463-7 | S |
| 1973-09-14 | Body mass index (BMI) [Ratio] | 21.4 kg/m2 | 39156-5 | S |
| 1973-09-14 | Systolic blood pressure | 110 mm[Hg] | 8480-6 | S |
| 1973-09-14 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 1973-09-14 | Heart rate | 68 /min | 8867-4 | S |
| 1973-09-14 | Respiratory rate | 14 /min | 9279-1 | S |
| 1973-09-14 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1973-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Professional cellist: solo and chamber concerts and recordings, and teaching; practices three to five hours a day; has cancelled most concerts this season because her fingers will not do what she asks
- S Married, with no children; lives in London with her husband, a pianist and conductor, who travels often for work; close friends among musicians. No relative is named or given a role in her care
- S Never smoker; alcohol a glass of wine with dinner some evenings; no drug use
- S Periods regular; uses condoms for contraception; not planning a pregnancy this year but would like to discuss it in future
- S Warm, funny and expressive; frightened that something is wrong with her hands and tired of being told it is stress
Functional status
- S Independent in daily activities; fine finger work slowed (buttons, writing, fingering); walking normal; tired by mid-afternoon
Mental status
- S Alert, warm and articulate; anxious about her hands; PHQ-2 negative; no thoughts of self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Nitrofurantoin macrocrystals 100 mg oral capsule, one capsule by mouth twice daily with food for 5 days
- S Methylprednisolone 1000 mg injection, 1 g intravenously over one hour once daily for 3 days
- S Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth daily
- S Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion
Procedures and immunizations
Procedures
- S MRI of the brain with and without gadolinium: 11 ovoid T2-hyperintense lesions, 3 mm to 9 mm, eight periventricular (several perpendicular to the ventricles), two juxtacortical and one in the right middle cerebellar peduncle; one periventricular lesion enhances; most lesions show a central vein; no mass, no meningeal enhancement
- S MRI of the cervical and thoracic spine with and without gadolinium (same session): a short dorsal lesion at C3 to C4, less than one vertebral segment long and occupying under half the cord's cross-section, with patchy enhancement; a second, non-enhancing lesion at T7; no cord swelling or compression
- S Lumbar puncture: clear fluid; white cells 6 per microliter (lymphocytes), protein 42 mg/dL, glucose normal; six oligoclonal bands in the cerebrospinal fluid not present in the serum; IgG index 0.86 (raised). Serum aquaporin-4 IgG by cell-based assay negative; HIV and syphilis serology negative
- S Advance care planning conversation, about 15 minutes
- S Occupational therapy assessment and program for hand function and fatigue: fine-motor and sensory re-education exercises for the fingers, graded return to practice in short blocks with rests, posture at the instrument, and energy management
- S Re-baseline MRI of the brain with and without gadolinium three months after starting ocrelizumab: no new or enlarging T2 lesions and no enhancing lesions; the previously enhancing periventricular lesion is smaller
Immunizations
- S 1970-02-06: Tdap vaccine
- S 1973-09-14: Influenza vaccine, this season (inactivated)
- S 1973-09-14: COVID-19 mRNA vaccine, this season's formula
- S 1973-03-23: Pneumococcal conjugate vaccine (PCV20), before B-cell therapy
- S 1973-03-23: Recombinant zoster vaccine, dose 1 of 2, before B-cell therapy
- S 1973-03-23: Hepatitis B vaccine (adjuvanted, two-dose series), dose 1, before B-cell therapy
- S 1973-04-27: Hepatitis B vaccine (adjuvanted, two-dose series), dose 2
- S 1973-07-13: Recombinant zoster vaccine, dose 2 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| MRI of the brain and spine within one week and a neurology diagnosis within three weeks | 1973-03-23 | completed | MRI in three days, lumbar puncture in a week, diagnosis and consultation at two weeks |
| High-efficacy disease-modifying therapy started within six weeks of diagnosis, after screening and vaccinations | 1973-04-27 | completed | Ocrelizumab started three weeks after the diagnosis; PCV20, recombinant zoster and hepatitis B vaccines given first |
| Nine-hole peg times back to within 10 percent of normal in both hands, and full practice resumed | 1973-07-13 | completed | 19.0 seconds right and 20.5 seconds left at three months; practicing three hours a day |
| No evidence of disease activity at six months (no relapse, no new or enhancing MRI lesion, no disability progression) | 1973-10-12 | completed | No relapse; re-baseline MRI with no new or enhancing lesions; examination stable |
| 25-hydroxyvitamin D of 30 ng/mL or more | 1973-07-13 | completed | 34 ng/mL after 16 weeks of cholecalciferol |
| PHQ-9 below 10 throughout | 1973-10-12 | completed | PHQ-9 between 3 and 7 |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Neurology (multiple sclerosis) consultation within two weeks to review the MRI with her and make a diagnosis and plan | completed | GL-AAN-DMT-2018, GL-NICE-NG220 |
| Urgent work-up of a sensory syndrome of both hands with Lhermitte's sign: MRI of the brain and cervical and thoracic spine with gadolinium within a week; blood count, chemistry, vitamin B12 and TSH; lumbar puncture for oligoclonal bands if the MRI is suggestive; return at once for weakness, unsteadiness, loss of bladder control or loss of vision | completed | GL-MCDONALD-2017, GL-MAGNIMS-2021, GL-NICE-NG220 |
| Relapse treatment: methylprednisolone 1 g intravenously daily for three days for a relapse that limits her hand function, after excluding infection; occupational therapy for hand function and energy management | completed | GL-NICE-NG220, GL-ECTRIMS-2018 |
| Early high-efficacy disease-modifying therapy with ocrelizumab: 300 mg intravenously on days 1 and 15, then 600 mg every six months, with premedication; chosen over natalizumab because the JCV antibody is positive and over ofatumumab at her preference for twice-yearly infusions; before the first dose, hepatitis B screening, varicella and measles immunity, immunoglobulins, a pregnancy test, and inactivated vaccines at least two weeks ahead; contraception during treatment | completed | GL-AAN-DMT-2018, GL-ECTRIMS-2018, GL-OPERA-2017, GL-AAN-VACC-2019 |
| Vitamin D: cholecalciferol 4000 units daily to correct deficiency, with a level after three months; not as a treatment for multiple sclerosis | completed | GL-NICE-NG220 |
| Monitoring on ocrelizumab: re-baseline MRI of the brain three to six months after starting, then yearly; blood count and immunoglobulins before each dose; infection and pseudo-relapse teaching; pregnancy planning, with conception timed after a dose | completed | GL-MAGNIMS-2021, GL-ECTRIMS-2018, GL-AAN-DMT-2018 |
| Fatigue, mood and work: screening for depression and sleep problems at each visit, plain explanations with written information, and a plan built around her practice, performing and teaching; she decides who is told and who receives each note | completed | GL-NICE-NG220, GL-USPSTF-DEP-2023 |
Planned encounters
- 1973-03-09 — Three weeks of numbness and clumsiness in the fingers of both hands, with Lhermitte's sign and fatigue, in a professional cellist of 28: examination, blood tests, and urgent MRI of the brain and spine (ENC-001)
- 1973-03-23 — Diagnosis of relapsing-remitting multiple sclerosis: neurology consultation, treatment of the relapse, choice of high-efficacy disease-modifying therapy, and vaccinations before B-cell therapy (ENC-002)
- 1973-04-27 — Second half-dose of the first ocrelizumab course: recovery of hand function, infusion reactions, vaccination, practice and work (ENC-003)
- 1973-06-15 — Same-day sick visit for cystitis with a pseudo-relapse (ENC-006, unscheduled)
- 1973-07-13 — Three months on ocrelizumab: re-baseline MRI, B-cell depletion, fatigue, vitamin D and hand function (ENC-004)
- 1973-09-14 — Periodic adult preventive visit on B-cell therapy (ENC-007)
- 1973-10-12 — Six months: first 600 mg dose of ocrelizumab, no evidence of disease activity, immunoglobulins, vaccination response, pregnancy planning and her return to performing (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Sick Visit
- Progress note 05 — Focused Visit (Follow-up)
- Progress note 06 — Preventive Visit
- Progress note 07 — Focused Visit (Care-plan review)
- Neurology (multiple sclerosis) referral
- Neurology (multiple sclerosis) consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Sick Visit (XML)
- Progress note 05 — Focused Visit (Follow-up) (XML)
- Progress note 06 — Preventive Visit (XML)
- Progress note 07 — Focused Visit (Care-plan review) (XML)
- Neurology (multiple sclerosis) referral (XML)
- Neurology (multiple sclerosis) consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) | SAGE (Multiple Sclerosis Journal - Experimental, Translational and Clinical) | scholarly |
| SRC-0002 | Dacy LC, Rodriguez M. The interrupted concerto: Jacqueline du Pré and MS (Hektoen International, Fall 2014) | Hektoen International: A Journal of Medical Humanities | other |
| SRC-0003 | Jacqueline du Pré | Wikipedia | other |
| SRC-0004 | du Pré, Jacqueline (1945-1987) (Women in World History: A Biographical Encyclopedia) | Encyclopedia.com (Gale) | other |
| SRC-0005 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the application of the 2017 McDonald criteria and the 2024 revision, the decision to test aquaporin-4 but not MOG antibody, intravenous rather than oral methylprednisolone for the relapse, the choice of ocrelizumab over natalizumab (JCV antibody positive) and ofatumumab, the timing of vaccines before B-cell depletion, and the management of a pseudo-relapse with cystitis. |
| provenance review | not_started | She died in 1987; the recent-death rule does not apply, but her husband and siblings are living or recently living public people and none of them is named; contested family accounts are not used. Claims rest on a 2018 peer-reviewed review, an essay by two Mayo Clinic physicians, Wikipedia and Women in World History; everything clinical is synthetic. |
| safe messaging review | not_started | No mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail, and later disputed claims about it are not used. No relative is named or given a role in the modern episode. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.